2024-516617-20-00RecruitingPhase 3
Long-term Follow-up study for relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LL) patients previously treated with OC-1 cells.
Source: EU CTIS (euclinicaltrials.eu) · Last updated 11 Apr 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
To monitor patients with primary relapsed/refractory (R/R) CD1a-positive T-ALL/LL who received OC-1 cells, for 15 years following CAR-T infusion to assess the risk of delayed adverse events (AEs).
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 13 Jan 2025
- Start date
- 21 May 2025
- Lead sponsor
- Onechain Immunotherapeutics S.L.
- EU CT number
- 2024-516617-20-00
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 20
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- None. All patients who have received prior treatment with OC-1 cell investigational product are eligible for this long-term follow up (LTFU) study.
Who the study is looking for
- Patients previously treated with at least one fraction of OC-1 cell investigational product
- Patient or patient’s legal representative has provided signed and dated informed consent.
- Patient is able to comply with the study requirements.
Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital Clinic de Barcelona | Barcelona | Spain | Recruiting |
| Hospital Sant Joan De Deu Barcelona | Esplugues de Llobregat | Spain | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.